Transilax

Quick links to important sections

Transilax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Transilax

Quick Facts

Property Description
Active Ingredients Lactulose, Macrogol (Polyethylene Glycol)
Form Oral Solution or Powder for Oral Solution
Pharmacological Class Combined Osmotic Laxative / Gastrointestinal Agent
Common Use Relief from Constipation
Origin Synthetic/Derived

What Type of Medicine is Transilax?

Transilax is defined as a Combined Osmotic Laxative, falling within the broad category of Gastrointestinal Agents, and is formulated for oral administration. This classification highlights its reliance on the physical principle of osmosis to draw and retain water within the intestine. As a combination product, Transilax incorporates two distinct active ingredients, providing a dual, synergistic approach for the effective regulation of bowel function. The final dosage form is typically an Oral Solution or a powder prepared into an aqueous solution.

Composition: The Dual-Action Components of Transilax

The active composition of Transilax is based on the therapeutic partnership between Lactulose (a synthetic disaccharide) and Macrogol (a synthetic polyether polymer), both of which are synthetic/derived substances. These two components are delivered within a basic Aqueous Solution or excipient mixture. This combination is designed to provide a comprehensive mechanism to address constipation when a single osmotic agent may be insufficient.

General Purpose and Non-Systemic Action

The general purpose of Transilax is to provide effective support for bowel regulation and sustained relief from constipation, such as cases of chronic idiopathic constipation. The medicine is designed with a deliberate non-systemic mechanism, meaning its primary therapeutic effects are physically contained within the gastrointestinal tract, minimizing absorption into the systemic circulation. This non-systemic approach relies on the combined osmotic activity that physically ensures significant hydration and softening of the stool mass, which naturally facilitates passage and supports the body's effort to restore normal bowel function.

What side effects are possible with Transilax?

Possible Side Effects and Safety Information

The safety profile of Transilax, which contains Lactulose and Macrogol, is primarily characterized by effects localized to the gastrointestinal (GI) tract. The frequency of these adverse reactions is classified by regulatory authorities using established tiers.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects System-Organ Class
Very Common (ge 1/10) Diarrhoea, flatulence, abdominal pain, borborygmi Gastrointestinal disorders
Common (ge 1/100 to < 1/10) Nausea, vomiting, anorectal discomfort Gastrointestinal disorders
Uncommon (ge 1/1,000 to < 1/100) Abdominal distension, urgency to defecate, electrolyte imbalance (due to diarrhoea) Gastrointestinal, Metabolism

Serious Adverse Reactions and Safety Patterns

Potential serious adverse reactions officially documented are linked to fluid loss. Electrolyte disturbances (such as hypokalaemia) and dehydration may occur secondary to unadjusted, prolonged, or excessive use leading to severe diarrhoea. Rare but serious hypersensitivity reactions, including anaphylaxis and angioedema, have also been documented.

Flatulence and abdominal cramping are often transient and may occur during the initial days of treatment. Conversely, the risks of electrolyte imbalance and dehydration are typically associated with chronic, unadjusted use.

Safety-Related Restrictions and Special Populations

Use of Transilax is formally contraindicated by regulatory bodies in the presence of conditions like known hypersensitivity, bowel obstruction, ileus, or severe inflammatory conditions of the intestinal tract (e.g., Crohn's disease, ulcerative colitis).

Elderly patients and those in poor general condition require particular consideration. If they are on long-term treatment, periodic control of electrolytes is indicated due to the elevated risk of imbalance from potential fluid loss.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Transilax, often a phosphate-containing laxative, as posing a risk of serious systemic harm when maximum labeled doses are exceeded. This is not a description of general side effects, but a warning about acute toxicity.

Overdose exposure, particularly when using more than one dose within a 24-hour period, is primarily associated with severe dehydration and significant electrolyte imbalances. These fluid and mineral disturbances can critically affect the function of vital organs.

Clinical Manifestations and Risk Factors

Symptoms of a severe overdose can include profound changes in serum electrolyte levels, severe abdominal pain, vomiting, and diarrhea. The most critical adverse effects are documented as serious complications involving the kidneys and the heart, which in rare cases have resulted in death.

Certain patient populations carry a higher risk of serious adverse effects from overdose, including individuals older than 55 years, those with pre-existing kidney disease, or a diagnosis of heart or kidney failure.

Emergency Response

Immediate medical attention is required if an overdose is suspected or if symptoms of kidney injury are observed after use. Regulatory warnings specify signs such as drowsiness, sluggishness, a significant decrease in the amount of urine produced, or swelling of the legs and feet.

In the event of using more than the recommended amount, it is officially advised to get medical help right away or contact a Poison Control center. This action is critical for minimizing the potential for serious organ damage.

Therapeutic Uses of Transilax

Main Uses of Transilax

Transilax is an osmotic laxative primarily used for the symptomatic treatment of constipation in adults and children. Its active mechanism involves increasing the water content within the intestinal tract, which softens the stool and facilitates easier passage through the colon.

Primary Indications

  • Short-term Relief of Constipation: It is frequently used to manage occasional episodes of irregular bowel movements.
  • Chronic Functional Constipation: It may be utilized for longer-term management of persistent constipation under clinical supervision.
  • Stool Softening: By promoting hydration within the bowel, it helps alleviate the discomfort associated with passing hard or dry stools.

Benefits and Mechanism of Action

The therapeutic benefit of Transilax is derived from its ability to regulate bowel function without being absorbed into the bloodstream.

Key Benefits

  • Predictable Action: It works by retaining water in the digestive system, which naturally stimulates the urge to defecate as the stool volume increases.
  • Non-Stimulant Properties: Unlike stimulant laxatives, it does not act directly on the nerves of the intestinal wall, which may reduce the risk of cramping or sudden urgency.
  • Metabolic Inertia: The active ingredients generally pass through the digestive system without being fermented by gut bacteria or absorbed by the body, maintaining a consistent effect throughout the treatment period.

Eligibility and Restrictions for Use

Who Can and Cannot Use Transilax?

This information describes official regulatory rules regarding eligibility and restrictions for using Transilax, based on governmental documentation.


Eligibility Criteria

Transilax is officially indicated for use in adults and children 17 years of age and older. Use in children younger than 17 years requires determination by a healthcare provider. The medicine is classified as Pregnancy Category C.


Contraindications and Restrictions

The medicine must not be used (contraindicated) by individuals with the following conditions:

  • Known or suspected bowel obstruction
  • Appendicitis
  • Inflamed bowel disease
  • Perforated bowel
  • Hypersensitivity (allergy) to polyethylene glycol or any component.

Use is not recommended for patients with existing kidney disease. Individuals with other stomach or bowel problems, such as irritable bowel syndrome, should use Transilax with caution, as the medication may worsen these conditions. Treatment duration is generally restricted to a maximum of 7 days unless otherwise directed by a doctor.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Transilax, a combination osmotic laxative, centers on effects within the gastrointestinal tract and the potential for reinforcing specific physiological risks, as documented in regulatory labels. The product does not have documented systemic metabolic interactions (e.g., CYP enzyme effects).

Pharmacodynamic and Exposure Interactions

Interacting Substance Category Official Interaction Description
Nonabsorbable Antacids May prevent the desired drop in colonic pH caused by the Lactulose component, resulting in a possible reduction in therapeutic efficacy.
Medicines Affecting Fluid/Electrolytes Co-administration with the Macrogol component may increase the risk of serious fluid and electrolyte abnormalities (e.g., when used alongside Diuretics, NSAIDs, or ACE inhibitors).
All Oral Medications The accelerated intestinal transit caused by the osmotic agents can reduce the absorption and systemic exposure of concomitantly administered oral medicines.

Interaction-Related Requirements

The risk of reduced absorption for other medicines necessitates a regulatory requirement for timing separation. Official instructions often specify that other oral medications must not be taken within a defined period (e.g., 1 hour) before or after the osmotic laxative dose to mitigate the potential for lower systemic exposure.

Population-Based Restrictions

Lactulose is formally contraindicated in patients who require a low galactose diet due to the presence of minor amounts of galactose in the formulation. Caution is also advised when co-administering with drugs that lower the seizure threshold, due to the potential for electrolyte imbalances caused by the osmotic effect.

Mechanism of Action

Osmotic Action and Intraluminal Fluid Dynamics

Transilax acts as an osmotic agent within the luminal space of the colon, its primary biological target. The drug remains non-absorbed, establishing a high concentration gradient that prevents water reabsorption from the digestive tract and actively draws extra fluid into the bowel via osmosis. This mechanistic cascade results in the hydration and softening of the solid waste material, a key physiological consequence of its action on fluid dynamics.


Mechanical Stimulation via Volume Expansion

The second mechanistic domain involves the physiological consequences of the retained fluid: the significant expansion of the intraluminal volume (bulk). This increased bulk serves as a direct mechanical stimulus against the colonic smooth muscle walls, engaging the mechanosensory network. This physical pressure mechanically engages the peristaltic reflex, contributing to the enhanced propagation of luminal contents and shaping the drug's observed physiological effect.

Dosage and Administration Information

How to Use Transilax

Transilax, a combination of Lactulose and Macrogol (Polyethylene Glycol), is strictly for oral administration and is supplied as either an oral solution or a powder for oral solution. The specific method of use depends on the form being administered.

Standard Dosing and Schedule

For adults, dosing for the Lactulose component typically begins and is maintained within a range of 15 mL to 30 mL (10 g to 20 g) daily. The Macrogol component is usually taken as 17 g (or one dose unit) once daily. The standard administration frequency for Transilax is once daily, though the dose may be divided or adjusted as needed.

Dose Titration: A core principle of use is that the daily dosage is titrated (adjusted) until the individual achieves a desired functional response, which is often described as 2 to 3 soft stools per day. The onset of action is not immediate; a period of 24 to 48 hours may be required to produce a normal bowel movement.

Preparation and Contextual Intake

Preparation: If using the powder for oral solution form, the powder must be fully dissolved by mixing it into a specific volume of liquid, such as 4 to 8 ounces (120 to 240 mL) of water, juice, or other fluid, immediately before consumption.

Fluid Intake: Due to the medication's osmotic mechanism, adequate daily fluid intake (e.g., 1.5 to 2 L or 6 to 8 glasses) is advised to be maintained throughout the treatment course. The medicine can generally be taken with or without food. For the oral solution, a single dose should be swallowed in one motion.

Duration: Use ranges from short-term for temporary issues to long-term as part of a chronic management plan. No specific dosage adjustment is required for older adults, though pediatric dosing must be determined by a healthcare provider.

Recent Clinical Evidence

Evidence for Use in Chronic Idiopathic Constipation (CIC)

Research exploring the use of combined osmotic laxatives for Chronic Idiopathic Constipation (CIC) was primarily supported by Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies monitored outcomes related to physical discomfort, measuring the frequency of spontaneous bowel movements and assessing stool consistency in adult and older adult populations. Findings contribute to the broader evidence landscape, but the long-term effects for periods exceeding one year are not fully established, and evidence quality varies across studies.


Evidence for Use in Functional Constipation in Children

The research for the use of this medicine in children with functional constipation was evaluated in controlled studies, often comparing the combination against a single osmotic agent. These studies monitored outcomes reflecting daily functioning, such as changes in stool frequency, painful defecation episodes, and consistency. While the general framework for use in children is established, subgroup findings are uncertain for very specific age ranges, and evidence is limited regarding long-term outcomes tracking symptom recurrence.


Long-Term Research and Durability of Effect

Research has explored outcomes over defined time intervals, with some studies monitoring responses for up to 6 to 12 months to understand sustained use. These studies contribute to understanding symptom patterns during conditions characterized by fluctuating manifestations. However, long-term effects are not fully established, and there is limited information for outcomes of the combination product extending beyond one year. Research is ongoing to better characterize the sustained stability of response.


Understanding the Scientific Uncertainty

The existing research highlights what is known and what is still uncertain. The medicine was studied for both older adults and children, and specific research exploring the use of the combination for Opioid-Induced Constipation (OIC) has also been conducted. However, comparative evidence is lacking between the specific dual-combination product and many other single-agent laxatives or newer prescription medications. Furthermore, sample sizes were modest in some of the smaller efficacy trials, meaning findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References Clinical Guideline: American College of Gastroenterology (ACG) on the Management of Chronic Constipation

Frequently Asked Questions (FAQ)

Common questions about Transilax (FAQ)

Q: Is Transilax considered a long-term treatment or just for occasional use?

A: Official regulatory documents indicate that Transilax can be used for a short duration for temporary issues. However, longer-term use is described as part of a chronic management plan requiring supervision. The appropriate duration of use is determined based on the individual’s condition.

Q: Do I need to change my diet while I am using Transilax?

A: Official patient guidance primarily emphasizes the importance of maintaining adequate daily fluid intake while using this medicine. Generally, the official documents do not describe specific changes to your food intake beyond the general importance of hydration. The medicine can typically be taken with or without food.

Q: Are there any known foods or vitamins that can affect how Transilax works?

A: Regulatory information notes that certain liquids, such as juice or milk, may be used when preparing the oral solution. Official interaction profiles typically focus on other oral medicines and the potential for reduced absorption. Patients with a known contraindication, like a low galactose diet, should be aware of the formulation’s composition.

Q: Can Transilax cause tiredness or make me drowsy?

A: Drowsiness is not listed as a common or frequently reported side effect in official product information. However, regulatory warnings exist about the risk of severe fluid and electrolyte imbalance from unadjusted, excessive use. Symptoms related to these serious adverse reactions are listed as adverse effects that, in rare instances, may include symptoms like confusion.

Q: What should I do if I miss a time I was supposed to use Transilax?

A: According to official administration instructions for the active components, if a dose is forgotten, the patient should skip the missed dose. The patient is advised to take the next scheduled dose at the usual time. Official guidance states that patients should never take a double dose to compensate for the forgotten one.

Q: Can Transilax affect birth control or other hormonal medications?

A: Official warnings state that the accelerated intestinal transit caused by Transilax may reduce the absorption and systemic exposure of other oral medicines. Regulatory labels advise timing separation between this medicine and other oral medications. Public health sources caution that severe diarrhea or vomiting caused by the laxative effect may specifically reduce the effectiveness of oral contraceptive pills.

Q: How is Transilax different from a fiber supplement?

A: Official documents classify Transilax as a Combined Osmotic Laxative, meaning it works by drawing water into the intestine to soften the stool. In contrast, fiber supplements are typically classified as Bulk-Forming Laxatives, which promote bowel function by increasing the stool volume directly through undigested matter. This represents a difference in the primary mechanism of action.

Q: Is there any research evidence on using Transilax during pregnancy or while breastfeeding?

A: The medicine is classified as Pregnancy Category C in official documents, indicating limited formal studies. One of the active components (Macrogol) is noted in regulatory contexts as being poorly absorbed, which is a factor in its established use during pregnancy.

Q: Does Transilax have an effect on blood sugar levels?

A: Official product information states that the Lactulose component is derived from a disaccharide and contains minor amounts of other sugars. Because of this composition, patients who have diabetes should be aware of this composition. Studies have examined the effect of the recommended dosage and generally indicate minimal impact on blood glucose levels in non-insulin-dependent patients.

Q: Why is Transilax available only with a healthcare provider's authorization?

A: Regulatory labels for the active component Lactulose indicate that it is classified as a prescription drug used for specific conditions, such as constipation. This prescription status means that a healthcare provider’s authorization is required to obtain the medication.

Q: What does 'contraindication' mean in relation to Transilax?

A: A contraindication is a term used in official regulatory documentation to describe a specific circumstance or condition where the medication should not be used. This is because using the medicine in that situation, such as having a bowel obstruction, poses a significant and unacceptable risk to the patient.

Q: Do the side effects of Transilax usually go away after a few weeks?

A: According to the official safety information, common side effects such as flatulence, gas, and abdominal cramping are often transient. These minor effects are typically reported during the initial days of treatment as the body adjusts to the medicine.

Q: Can Transilax be used alongside supplements like magnesium?

A: The product information states that combining osmotic laxatives like Transilax with other similar medications or supplements, such as magnesium salts, may increase the risk of serious fluid and electrolyte abnormalities.

Q: Can I take Transilax if I have a history of heart problems?

A: While a history of heart problems is not listed as a formal contraindication in official labels, the product warnings highlight the potential for severe fluid and electrolyte abnormalities in rare instances. These imbalances are noted as having the potential to lead to complications such as cardiac arrhythmias.

Q: Do interactions with Transilax mean I should stop taking the other medicine?

A: Regulatory documents generally advise timing separation between taking Transilax and other oral medicines (e.g., 1 hour) to mitigate reduced absorption. Official guidance states that decisions regarding stopping or changing existing medicines are the purview of the patient's healthcare provider.

Q: What is the function of the inactive ingredients in Transilax?

A: Official regulatory labels list the inactive ingredients (excipients) used in the formulation, such as purified water, flavoring, or pH adjusters. Their primary function is typically to maintain the product's stability, improve the taste, or ensure the appropriate chemical balance of the solution.

Q: Does Transilax affect the absorption of nutrients from food?

A: Official interaction profiles primarily state that the accelerated intestinal transit caused by the medicine can reduce the systemic absorption of oral medicines. The official documents do not explicitly detail the specific impact on the absorption of nutrients from consumed food.

How should Transilax be stored and disposed of?

Transilax must be stored according to strict regulatory conditions to maintain its stability and effectiveness. The product must be kept in its original container, which must be securely tightly closed. Storage is required at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from freezing, excess heat, light, and moisture. Once the powder is reconstituted into a solution, it should be used within a short stability period, such as six hours. A critical requirement is to store the medicine out of the sight and reach of children.

For disposal, unused or expired Transilax must not be flushed down a sink or thrown into household trash. Instead, the official guidance is to consult a pharmacist or healthcare professional for advice on local take-back programs or proper disposal protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Transilax found in:

A-Z Index: